Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biopharmaceutical company focused on advancing first-in-class, non-opioid, treatments for chronic and acute ...
In exchange, the Company has agreed to issue to Conjoint 284.2638 shares of Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share ... includes IMC-1 and IMC-2, which ...
In exchange, the Company has agreed to issue to Conjoint 284.2638 shares of Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share ... includes IMC-1 and IMC-2, which ...
Dogwood’s antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed-dose combinations of anti-herpes antivirals and the anti-inflammatory agent celecoxib. These combination ...
One of the most exciting developments in Immunocore’s pipeline is IMC-M113V, a potential treatment for HIV. Recent Phase 1 data presented at the Conference on Retroviruses and Opportunistic Infections ...
The Company further advanced its clinical pipeline, enrolling patients in its three Phase 3 trials, initiating patient dosing in its Phase 1 trial with IMC-P115C, its half-life extended candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback